Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01874353 · MORE INFO

Limitations, agreements, and source contact

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy · Source last updated 2026-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
The outbreak of the COVID-19 pandemic shortly before the final OS DCO (03 February 2020) was not judged to meaningfully impact the overall quality of the study, including the conduct, data, and interpretation of results.
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca
phone
1-877-240-9479
title
Global Clinical Program Lead
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
The outbreak of the COVID-19 pandemic shortly before the final OS DCO (03 February 2020) was not judged to meaningfully impact the overall quality of the study, including the conduct, data, and interpretation of results.
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca
phone
1-877-240-9479
title
Global Clinical Program Lead

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice